Skip to main content
  • Oral presentation
  • Open access
  • Published:

LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers


To determine the toxicity and NY-ESO-1-specific immune responses induced by immunization with rV-NY-ESO-1 or rF-NY-ESO-1.

Study design

Eligible patients (pts) for the first part of the study were HLA-A2+ with advanced NY-ESO-1/LAGE+ tumors assessed by RT-PCR or immunohistochemistry. For the second part, pts were enrolled irrespective of the HLA type. Four injections of rV-NY-ESO-1, 3.1 × 107 pfu i.d., or rF-NY-ESO-1, 7.41 × 107 pfu s.c., were administered four times at 4 week intervals in part 1. Pts enrolled to part 2 received 2 injections of rV-NY-ESO-1, 3.1 × 107 pfu i.d., followed by multiple injections of rF-NY-ESO-1, 7.41 × 107 at monthly intervals in case there was no evidence for progressive disease during vaccination. Toxicity was evaluated every 2 weeks. Delayed-type hypersensitivity (DTH) against HLA-A2 binding NY-ESO-1 peptides was assessed at baseline and after the last vaccination in HLA-A2+ pts. Immunogenicity was assessed by ELISPOT and tetramer analysis against HLA-A2 binding NY-ESO-1 peptides.


29 pts with different types of cancer were enrolled, 9 pts are ongoing, 11 completed at least 4 cycles of treatment, 9 were withdrawn for disease progression or at their own discretion. No remarkable toxicities occured. Positive post-vaccination DTH reactions against 2 HLA-A2 binding NY-ESO-1 peptides occurred in 6/6 pts tested. At baseline all HLA-A2+ pts of part 1 were NY-ESO-1 serum antibody- and CD8+ T-cell negative. In 2 pts a conversion of NY-ESO-1 serum antibody was observed after 3 vaccinations. In 9 pts for whom immune assay data are available, NY-ESO-1 specific CD8+ T-cell responses were induced during vaccination. After 4 injections maximum ELISPOTS ranged between 160–800 per 50,000 CD8+ T-cells in the 2 vaccinia pts and 100–500 in the 2 fowlpox pts as confirmed by tetramer assays. At 4 months 14 pts were found to have stable disease. 1 pt experienced a partial remission of subcutaneous and peritoneal melanoma metastases after 3 months of immunization. Assessments are underway for NY-ESO-1 specific T cell responses restricted by non-HLA-A2 and HLA class II alleles.


Immunization with recombinant vaccinia- and fowlpox-NY-ESO-1 is safe and induces NY-ESO-1 specific immune responses.

Author information

Authors and Affiliations


Corresponding author

Correspondence to A Bender.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bender, A., Karbach, J., Neumann, A. et al. LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers. Cancer Cell Int 4 (Suppl 1), S18 (2004).

Download citation

  • Received:

  • Published:

  • DOI: